8-K: MoonLake Reports Q3 2025 Results, Advances Sonelokimab Trials

MoonLake Immunotherapeutics announced its third quarter 2025 financial results and positive new clinical data for its Nanobody Sonelokimab across multiple inflammatory disease trials.

Summary

• Ended Q3 2025 with $380.5 million in cash, cash equivalents, and short-term marketable debt securities, which, together with funds from a previously announced debt facility, are expected to provide runway into the second half of 2027.
• Reported clinically meaningful and statistically significant benefit from its Phase 2 LEDA clinical trial of Sonelokimab (SLK) in adult patients with Palmoplantar Pustulosis (PPP), with a mean percent change from baseline in PPPASI of 64% at week 16, and 39% of patients achieving PPPASI75.
• An interim analysis of long-term data from the VELA-1 and VELA-2 clinical trials in adults with Hidradenitis Suppurativa (HS), as well as an interim analysis of its VELA-TEEN clinical trial in adolescent HS, demonstrated continuous clinical improvement and competitive potential for SLK.
• Confirmed a Type B meeting with the U.S. Food and Drug Administration (FDA) on December 15, 2025, to discuss the adequacy of the current clinical evidence package of SLK in HS to support a Biologics License Application (BLA).
• Research and development expenses for the quarter ended September 30, 2025, were $60.6 million, an increase of $10.8 million from $49.8 million in the previous quarter, driven by clinical trial ramp-up and BLA preparation.
• General and administrative expenses for the quarter ended September 30, 2025, were $10.8 million, similar to the $10.9 million incurred in the previous quarter.
• Net loss for the quarter ended September 30, 2025, was $(70.694) million, compared to $(56.051) million for the quarter ended June 30, 2025.
• Basic and diluted net loss per share attributable to controlling interests shareholders was $(1.10) for Q3 2025, compared to $(0.87) for Q2 2025.

Sentiment

Score: 7

Explanation: While financial losses increased due to R&D ramp-up, the positive clinical trial data for Sonelokimab across multiple indications, particularly the statistically significant benefit in PPP and promising interim results in HS, coupled with a strong cash runway and confirmed FDA meeting, indicate significant progress and future potential for the company's lead asset.

Positives

• Strong cash, cash equivalents, and short-term marketable debt securities totaling $380.5 million as of September 30, 2025, providing an expected cash runway into the second half of 2027.
• Sonelokimab (SLK) demonstrated clinically meaningful and statistically significant benefit in the Phase 2 LEDA trial for Palmoplantar Pustulosis (PPP), with 64% mean PPPASI change and 39% achieving PPPASI75 at week 16.
• Interim analysis of long-term data from VELA-1 and VELA-2 (adult HS) showed continuous clinical improvement and potentially competitive advantages.
• Interim analysis of the VELA-TEEN trial (adolescent HS) showed 46% of patients achieved a HiSCR75 response at week 16 (n=11).
• A Type B meeting with the FDA is confirmed for December 15, 2025, to discuss the Biologics License Application (BLA) submission for SLK in HS.
• Other clinical trials (Phase 2 S-OLARIS in axSpA and Phase 3 IZAR trials in PsA) are progressing well, supporting a catalyst-rich roadmap over the next 12 months.
• The safety profile of SLK in the LEDA trial was consistent with previous trials, with no new safety signals detected.

Negatives

• Research and development expenses increased significantly to $60.6 million in Q3 2025 from $49.8 million in Q2 2025.
• Net loss increased to $(70.694) million in Q3 2025 from $(56.051) million in Q2 2025.
• Basic and diluted net loss per share increased to $(1.10) in Q3 2025 from $(0.87) in Q2 2025.
• In the VELA-2 trial, intercurrent events in the higher-than-expected placebo arm precluded the study from achieving statistical significance in the week 16 primary endpoint using the composite strategy (HiSCR75, delta to placebo of 9%, p=0.053).

Risks

• Interim data analyses conducted prior to database lock and based on a limited number of patients having reached the relevant time point may not be consistent with final data.
• Risks and uncertainties associated with MoonLake's business in general and limited operating history.
• Difficulty enrolling patients in clinical trials.
• State and federal healthcare reform measures could result in reduced demand for MoonLake's product candidates.
• Reliance on third parties to conduct and support preclinical studies and clinical trials.
• Actual results could differ materially from forward-looking statements as a result of various risks and uncertainties.

Future Outlook

MoonLake expects its current cash and debt facility to fund operations into the second half of 2027. The company anticipates a catalyst-rich roadmap over the next 12 months, including data releases from the Phase 2 S-OLARIS trial in axSpA and Phase 3 IZAR trials in PsA. A Phase 3 trial in PPP is expected to commence in Q3 2026, and a Biologics License Application (BLA) submission is targeted for Q3/Q4 2026, with data from the VELA-TEEN trial expected to be part of this submission.

Industry Context

MoonLake Immunotherapeutics is developing Sonelokimab (SLK), a Nanobody targeting IL-17A and IL-17F, for inflammatory diseases with significant unmet needs such as hidradenitis suppurativa (HS), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), and palmoplantar pustulosis (PPP). The positive Phase 2 data in PPP, a condition with no currently approved therapies, highlights SLK's potential to address critical gaps in treatment. The ongoing progress in HS and PsA trials, coupled with the confirmed FDA meeting for BLA discussion, positions MoonLake as a key player in the competitive inflammatory disease market, particularly against existing IL-17 inhibitors and other biologics. The focus on higher clinical response levels like HiSCR75 in HS and ACR50/MDA in PsA aims to differentiate SLK in efficacy.

Comparison to Industry Standards

• Sonelokimab's mechanism of inhibiting IL-17A and IL-17F positions it against other IL-17 inhibitors like secukinumab (Cosentyx) and ixekizumab (Taltz), which primarily target IL-17A. The dual inhibition could offer broader efficacy.
• In Palmoplantar Pustulosis (PPP), SLK demonstrated a 64% mean PPPASI change and 39% achieved PPPASI75 at week 16. This is significant as there are currently no approved therapies for PPP, setting a new benchmark if Phase 3 trials confirm these results.
• For Hidradenitis Suppurativa (HS), the VELA program uses HiSCR75 as a primary endpoint, a higher bar than the HiSCR50 often used in other trials (e.g., Humira, Cosentyx). The interim VELA-TEEN data showing 46% HiSCR75 at week 16 (n=11) suggests competitive potential, especially for an adolescent population where treatment options are limited.
• In Psoriatic Arthritis (PsA), the Phase 2 ARGO trial showed approximately 60% of patients treated with sonelokimab achieving an ACR50 response and Minimal Disease Activity (MDA) at week 24. This compares favorably to some existing treatments, and the IZAR-2 trial's inclusion of a risankizumab active reference arm (an IL-23 inhibitor) will provide direct comparative data against a leading biologic in the market.
• The safety profile of sonelokimab across trials (LEDA, VELA, ARGO) has been consistent with previous trials and generally well tolerated, similar to active controls like secukinumab in plaque-type psoriasis, which is a positive indicator for its competitive standing.

Stakeholder Impact

• Shareholders: Positive clinical data and a clear development roadmap could increase investor confidence, despite increased losses. The confirmed FDA meeting is a key de-risking event.
• Patients: Sonelokimab shows potential to offer new, effective treatment options for debilitating inflammatory diseases like PPP (where no approved therapies exist), HS, PsA, and axSpA, potentially improving quality of life.
• Employees: Continued progress in clinical trials and BLA preparation suggests stability and growth opportunities.
• Creditors: The strong cash position and expected runway into H2 2027 provide assurance regarding the company's ability to meet its financial obligations.

Next Steps

• Type B meeting with the FDA on December 15, 2025 (minutes expected within 30 days).
• Primary endpoint readout of Phase 2 S-OLARIS trial in axSpA in Q1 2026.
• 52-week data of VELA-1 and VELA-2 trials in HS in Q2 2026.
• Primary endpoint readout of Phase 3 IZAR-1 trial in PsA in Q2 2026.
• Primary endpoint readout of Phase 3 VELA-TEEN trial in adolescent HS in Q2 2026.
• Initiate Phase 3 trial in PPP in Q3 2026.
• Submission of a BLA in Q3/Q4 2026.
• Primary endpoint readout of Phase 3 IZAR-2 trial in PsA in H2 2026.

Key Dates

Recommendation

MoonLake Immunotherapeutics presents a mixed financial picture with increased losses driven by R&D expansion, but this is offset by highly encouraging clinical trial results for Sonelokimab across multiple indications, particularly in Palmoplantar Pustulosis and Hidradenitis Suppurativa. The confirmed FDA meeting for BLA discussion and a clear pipeline of upcoming catalysts provide significant de-risking and future growth potential. However, the increased burn rate and the slight miss on statistical significance in VELA-2's primary endpoint (though attributed to a higher placebo arm) warrant a cautious approach. The stock is likely to be volatile based on upcoming data readouts and regulatory milestones. A 'hold' recommendation allows investors to maintain exposure to the promising pipeline while monitoring financial performance and the outcomes of critical regulatory discussions and further trial results.

Keywords

MoonLake Immunotherapeutics, MLTX, Sonelokimab, SLK, Nanobody, Hidradenitis Suppurativa, HS, Psoriatic Arthritis, PsA, Axial Spondyloarthritis, axSpA, Palmoplantar Pustulosis, PPP, Clinical Trials, Phase 2, Phase 3, Biologics License Application, BLA, FDA, IL-17A, IL-17F, Biotechnology, Inflammatory Diseases, Financial Results, Q3 2025